Delving into the Latest Updates on Atezolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-PDL-1-Genentech/Roche, Atezolizumab (Genetical Recombination), Atezolizumab (genetical recombination) (JAN)

+ [11]

Target

PDL1

Action

inhibitors

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [11]

Active Indication

Extranodal NK-T-Cell LymphomaAdvanced Lung Non-Small Cell CarcinomaBreast Cancer+ [158]

Inactive Indication

Adenocarcinoma of large intestineAdvanced Bile Duct CarcinomaAdvanced biliary tract cancer+ [86]

Originator Organization

Genentech, Inc.Universitair Medisch Centrum Groningen

Active Organization

Hoffmann-La Roche, Inc.Roche Registration GmbH

Genentech, Inc.

+ [24]

Inactive Organization

Affimed GmbH

Sanofi

Basilea Pharmaceutica AG

+ [9]

License Organization

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [26]

Drug Highest PhaseApproved

First Approval Date

United States (18 May 2016),

Transitional Cell Carcinoma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 122091L

Source: *****

Sequence Code 4720027H

Source: *****

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Start Date20 Jan 2026

Sponsor / Collaborator

Kahr Bio Australia Pty Ltd

[+1]

NCT07276100

/ RecruitingPhase 2IIT

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular carcinoma (HCC) whose disease has progressed during prior atezolizumab-bevacizumab therapy. The study will also assess the safety and feasibility of this treatment strategy.
Primary Objective:
To determine whether FMT can restore or enhance response to atezolizumab and bevacizumab following disease progression.
Participants will:
Receive a fecal microbiota transplantation (FMT).
Resume treatment with atezolizumab and bevacizumab, administered every 3 weeks.

Start Date01 Jan 2026

Sponsor / Collaborator

IRCCS Azienda Ospedaliero-Universitaria di Bologna

NCT06492954

/ RecruitingPhase 1IIT

Phase 1b Trial of Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery in Patients With Pulmonary Recurrence of Osteosarcoma

This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma

Start Date01 Jan 2026

Sponsor / Collaborator

Emory University

[+1]

100 Clinical Results associated with Atezolizumab

Login to view more data

100 Translational Medicine associated with Atezolizumab

Login to view more data

100 Patents (Medical) associated with Atezolizumab

Login to view more data

4,499

Literatures (Medical) associated with Atezolizumab

01 Apr 2026·DEN open

A Rare Case of Immune‐related Adverse Events Localized to the Small Intestine

Article

Author: Morikawa, Ryo ; Taguchi, Towako ; Fukuda, Masayoshi ; Okamoto, Ryuichi ; Fujii, Toshimitsu ; Kanaya, Ryosuke ; Nemoto, Yasuhiro ; Yamamoto, Kurara ; Ohtsuka, Kazuo ; Shimizu, Hiromichi

ABSTRACT:

Enterocolitis is a common gastrointestinal manifestation of immune‐related adverse events (irAEs); however, only a few studies have reported on irAE enteritis with localized active inflammation in the small intestine. Here, we report the case of a 74‐year‐old man who developed diarrhea, abdominal pain, and oral intake difficulty and was subsequently hospitalized after receiving atezolizumab for pulmonary adenocarcinoma. Computed tomography and enterocolonoscopy revealed active inflammation in the small intestine but not in the colon, leading to the final diagnosis of irAE enteritis. After initiating prednisolone at a dose of 60 mg/day, his symptoms improved rapidly, and a follow‐up enterocolonoscopy revealed a marked reduction in inflammation. Being a relatively rare gastrointestinal toxicity, irAE enteritis often goes unrecognized due to diagnostic challenges, but can lead to serious AEs such as perforation. Therefore, even if colonoscopy findings are normal, a thorough examination of the small intestine is essential for patients who develop gastrointestinal symptoms while undergoing immune checkpoint inhibitor therapy. We herein report a rare case of irAE enteritis confirmed through endoscopic and pathological examination, which has not been previously reported.

01 Apr 2026·DEN open

A Case of Obstructive Jaundice due to Bile Duct Tumor Thrombus of Hepatocellular Carcinoma Diagnosed by Peroral Cholangioscopy

Article

Author: Tokumaru, Tomoko ; Endo, Mizuki ; Kinoshita, Keisuke ; Uchida, Takuro ; Murakami, Kazunari ; Okamoto, Kazuhisa ; Saito, Tomoko ; Kodama, Masaaki ; Iwao, Masao ; Arakawa, Mie

Abstract:

While hepatocellular carcinoma (HCC) often invades the portal or hepatic vein to form tumor thrombus, tumor thrombus in the bile duct is rare. In such cases, differentiation from intrahepatic cholangiocarcinoma is difficult, and the tumor often appears as a smooth, yellowish‐white, polypoid mass within the bile duct lumen. We report herein a case of obstructive jaundice due to bile duct tumor thrombus of HCC diagnosed by peroral cholangioscopy (POCS). A 64‐year‐old man presented with epigastralgia and jaundice. Contrast‐enhanced computed tomography revealed an irregular mass with hypoenhancement in liver segment S8, along with dilatation of the right intrahepatic bile duct due to the invading tumor. The hepatic mass was poorly visualized on ultrasound, making percutaneous liver tumor biopsy difficult. POCS was performed after endoscopic retrograde cholangiopancreatography for biopsy of the intrahepatic bile duct tumor thrombus. POCS clearly revealed a smooth, yellowish‐white, polypoid tumor in the right intrahepatic bile duct, and a biopsy of the tumor was performed under POCS. Based on the pathological findings, HCC was diagnosed, and chemotherapy with atezolizumab and bevacizumab was initiated.

01 Jan 2026·Value in Health Regional Issues

Real-World Effectiveness and Cost-Utility Analysis of Second-Line Immunotherapy for Non-Oncogene-Addicted Advanced Non-Small Cell Lung Cancer

Article

Author: Preedachitkul, Rinrada ; Chitpim, Natthakan ; Khunakorncharatphong, Anon ; Thamlikitkul, Lucksamon ; Horugsa, Chulamas ; Sawasdisara, Sasiporn ; Srinonprasert, Varalak

OBJECTIVES:

To determine the cost-effectiveness of second-line immune checkpoint inhibitors (ICIs) compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) using real-world patient-level treatment effectiveness, cost, and utility data.

METHODS:

Medical records of patients with NSCLC receiving second-line ICIs or chemotherapy at Siriraj Hospital, Bangkok, Thailand from January 2016 to May 2023 were reviewed to evaluate treatment effectiveness and direct medical costs. Patients receiving treatment from July 2023 to March 2024 were interviewed to determine utility and direct nonmedical costs. A semi-Markov model was used to analyze the lifetime costs and health outcomes from societal perspective. One-way and probabilistic sensitivity analyses and scenario analyses were performed.

RESULTS:

Data were collected from 209 patients (72 and 137 patients received second-line ICIs and chemotherapy, respectively). Second-line ICIs significantly improved overall survival (hazard ratio 0.64, 95% confidence interval 0.47-0.89, P = .008) and increased the quality-adjusted life-years (QALYs) from 0.54 to 1.11, resulting in QALY gain of 0.57; lifetime cost increased from 17 204 US dollar (USD) to 34 424 USD. Second-line ICI incremental cost-effectiveness ratio was 30 104 USD/QALY. Scenario analysis revealed that second-line ICIs were more cost-effective than chemotherapy for healthier patients (Eastern Cooperative Oncology Group 0-1) with incremental cost-effectiveness ratio of 9856 USD/QALY. Considering Thailand's willingness-to-pay threshold of 4444 USD/QALY, second-line ICIs could be cost-effective if the cost of atezolizumab was reduced by 86%.

CONCLUSION:

Second-line ICIs significantly improved survival in advanced NSCLC but are not cost-effective in Thailand. Drug price negotiation and patient subgroup prioritization would help make second-line ICIs more accessible.

1,526

News (Medical) associated with Atezolizumab

22 Dec 2025

·www.oryzon.com

ORYZON expands global patent protection for iadademstat with grant decision in Japan covering combinations with PD-1/PD-L1 inhibitors

MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, December 22nd, 2025 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Following formal grant, the patent is expected to remain in force until at least 2040, excluding any available patent term extensions. With this decision, Oryzon has now secured patent protection for these combinations in Europe, Japan, Australia and Russia, while corresponding patent applications continue to be prosecuted in other countries. “This Japanese grant represents another important milestone in building a robust patent portfolio around iadademstat,” said Neus Virgili, Oryzon’s Chief IP Officer. “It reinforces our strategy to protect the clinical use of iadademstat in combination with immune checkpoint inhibitors such as atezolizumab and durvalumab in small cell lung cancer (SCLC), an approach we are evaluating as part of iadademstat’s ongoing clinical development programs.” Iadademstat is being evaluated in combination with PD-L1 inhibitors (atezolizumab or durvalumab) in first line, extensive-disease SCLC patients in an ongoing Phase I/II trial conducted and sponsored by the U.S. National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Oryzon. The study is carried out at more than 30 clinical sites across the United States, including leading cancer institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins, City of Hope, Yale University and the University of Chicago, among others.

Patent Expiration

19 Dec 2025

·www.einpresswire.com

August 5, 2022 Posting | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Bavencio (avelumab) Imfinzi (durvalumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Cardiac failure FDA decided that no action is necessary at this time based on available information. Invega Sustenna (paliperidone palmitate) Invega Trinza (paliperidone palmitate) Lack of efficacy/effect FDA decided that no action is necessary at this time based on available information. Jevtana (cabazitaxel) Therapeutic product cross-reactivity FDA decided that no action is necessary at this time based on available information. Nexavar (sorafenib tosylate) Generic products containing sorafenib Cardiac failure The “Warnings and Precautions” section of the Nexavar labeling was updated December 2018 to include congestive heart failure. Example: Nexavar labeling PD-1 Blocking Antibody (Drug class) Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Cytokine release syndrome The “Warnings and Precautions” section of the PD-1 blocking antibody labeling was updated to include systemic inflammatory response syndrome. Example: Tecentriq labeling PD-1 Blocking Antibody (Drug Class) Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Tuberculosis FDA decided that no action is necessary at this time based on available information. Perjeta (pertuzumab) Angioedema The “Warnings and Precautions” section of the Perjeta labeling was updated September 2018 to include angioedema. Perjeta labeling Tecentriq (atezolizumab) Immune-mediated nephritis The “Warnings and Precautions” section of the Tecentriq labeling was updated November 2020 to include immune-mediated nephritis with renal dysfunction. Tecentriq labeling Tecentriq (atezolizumab) Stevens-Johnson syndrome The “Warnings and Precautions” section of the Tecentriq labeling was updated April 2018 to include Stevens Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN). Tecentriq labeling Xalkori (crizotinib) Blood creatine phosphokinase increase The “Adverse Reactions” section of the Xalkori labeling was updated June 2019 to include increased blood creatine phosphokinase. Xalkori labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalImmunotherapyBiosimilar

17 Dec 2025

·www.prnewswire.com

Breast Cancer Drugs Market to Reach USD 57.1 Billion by 2031 as Precision Oncology and Targeted Therapies Redefine Treatment Outcomes

AUSTIN, Texas and TOKYO, Dec. 17, 2025 /PRNewswire/ -- According to DataM Intelligence, the global Breast Cancer Drugs Market reached USD 32.4 billion in 2024 and is projected to expand to USD 57.1 billion by 2031, growing at a robust CAGR of 9.2% during the forecast period 2025–2031. This sustained growth reflects a decisive transformation in breast cancer care, where treatment strategies are shifting from broad, cytotoxic approaches toward biomarker-driven, targeted, and immune-based therapies. Advances in molecular diagnostics, earlier detection, and personalized treatment regimens are enabling clinicians to significantly improve survival outcomes while reducing long-term toxicity. By 2030, breast cancer therapeutics will be defined not by volume alone, but by clinical precision, durability of response, and lifecycle innovation across therapy lines. Request Executive Sample | Breast Cancer Drugs Market Intelligence: Why Breast Cancer Therapeutics Are Entering a New Growth Phase The expansion of the breast cancer drugs market is being driven by interconnected structural forces. Breast cancer incidence continues to rise globally, driven by aging populations, lifestyle factors, and improved screening programs. Breast cancer remains the most commonly diagnosed cancer among women worldwide, creating sustained demand for effective long-term treatment options. Treatment paradigms are becoming increasingly stratified. Instead of one-size-fits-all approaches, therapies are now selected based on hormone receptor status, HER2 expression, and emerging molecular signatures. This precision has expanded the use of targeted and combination therapies across early-stage and metastatic disease. Oncology innovation cycles have accelerated. Continuous pipeline development, label expansions, and novel mechanisms of action are extending treatment duration and increasing per-patient drug value. As a result, breast cancer drugs have become one of the most strategically important segments within global oncology markets. Market Segmentation Analysis By Cancer Type Hormone receptor-positive breast cancer represents the largest segment, accounting for approximately 64% of total market value in 2024, equivalent to USD 20.7 billion. This dominance reflects the high prevalence of estrogen and progesterone receptor-positive tumors and the long duration of treatment using hormonal and targeted agents. Continuous innovation in CDK4/6 inhibitors and endocrine combinations continues to expand this segment. HER2-positive breast cancer accounts for approximately 21% of the market, or around USD 6.8 billion. Advances in HER2-targeted monoclonal antibodies, antibody-drug conjugates, and combination regimens have dramatically improved outcomes, transforming HER2-positive disease into a highly treatable subtype. According to DataM Intelligence analysis, ' Hormone receptor-positive breast cancer will remain the largest revenue contributor through 2031, while HER2-positive and triple-negative segments will drive incremental growth through innovation'. By Therapy Targeted therapy is the leading therapeutic category, accounting for approximately 38% of total market revenue, or USD 12.3 billion in 2024. These therapies deliver high clinical efficacy with improved tolerability and are increasingly used across multiple lines of treatment. Hormonal therapy follows closely, representing about 27% of market value, or USD 8.7 billion. Its long treatment duration and widespread use in early and advanced disease ensure sustained demand. Chemotherapy accounts for approximately 22%, or USD 7.1 billion, reflecting its continued role in aggressive and late-stage disease despite growing competition from targeted approaches. Immunotherapy contributes the remaining 13%, or roughly USD 4.3 billion. While still emerging, immunotherapy is gaining traction, particularly in triple-negative breast cancer, and is expected to record the fastest growth rate through 2031. According to DataM Intelligence Analysis, ' Targeted and immune-based therapies will increasingly displace conventional chemotherapy in value terms, even as combination regimens remain standard practice'. By End User Hospitals represent the largest end-user segment, accounting for approximately 46% of total market value, or USD 14.9 billion. Complex treatment protocols, infusion therapies, and inpatient oncology care drive this dominance. Cancer centers account for around 29%, or USD 9.4 billion, reflecting the growing role of specialized oncology institutions in advanced and personalized treatment delivery. Clinics and ambulatory surgical centers together represent approximately 18%, or USD 5.8 billion, supported by the shift toward outpatient care and oral therapies. Request Customized Intelligence Aligned to Your Business Strategy: Regional Analysis United States The United States remains the largest breast cancer drugs market globally, accounting for approximately 41% of global revenue, equivalent to USD 13.3 billion in 2024. Key Drivers: High screening and diagnosis rates Early adoption of innovative oncology drugs Strong reimbursement frameworks High use of targeted and combination therapies By 2031, the U.S. breast cancer drugs market is expected to exceed USD 23 billion, maintaining its leadership position. Europe Europe accounts for approximately 30% of global market value, supported by strong public healthcare systems, early access to novel therapies, and increasing uptake of targeted oncology drugs. Asia-Pacific Asia-Pacific represents the fastest-growing regional market, driven by rising breast cancer incidence, expanding healthcare infrastructure, and improving access to advanced therapies, particularly in China, Japan, and South Korea. Competitive Landscape The major global players in the breast cancer drugs market include Novartis AG, F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eli Lilly and Company, AstraZeneca, Merck & Co., Inc., Biocon Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, and Onyx Pharmaceuticals Inc, and others. Novartis AG Key Breast Cancer Products: Kisqali (ribociclib); Piqray (alpelisib) Core strengths: Category leader in CDK4/6 inhibition (HR+/HER2–) with broad lifecycle expansion; precision oncology focus (PI3K pathway). Primary markets served: US, EU5, Japan, China, major APAC. F. Hoffmann-La Roche Ltd. Key Breast Cancer Products: Herceptin (trastuzumab), Perjeta (pertuzumab), Kadcyla (T-DM1), Phesgo (SC pertuzumab/trastuzumab), Tecentriq (atezolizumab) Core strengths: Global benchmark in HER2-targeted therapy across early + metastatic settings; strong diagnostics + biomarker integration ecosystem. Primary markets served: US, Europe, Japan, China, LATAM. Eli Lilly and Company Key Breast Cancer Products: Verzenio (abemaciclib) Core strengths: Major CDK4/6 franchise with strong traction in HR+/HER2– early and metastatic settings; breadth across adjuvant + advanced use cases. Primary markets served: US, Europe, Japan, China and broader APAC. AstraZeneca Key Breast Cancer Products: Faslodex (fulvestrant), Lynparza (olaparib) (with partner), Enhertu (trastuzumab deruxtecan) (with partner), Truqap (capivasertib) Core strengths: Strong portfolio spanning endocrine backbone, PARP inhibition (gBRCA), ADCs (HER2/low expression segments), and AKT pathway targeting—one of the broadest breast cancer pipelines. Primary markets served: US, EU5, Japan, China. Merck & Co., Inc. (MSD) Key Breast Cancer Products: Keytruda (pembrolizumab) Core strengths: Immuno-oncology leadership; strong combination development and label expansion strategy. Primary markets served: US, Europe, Japan, global. What will Define the Market by 2030–2031 By 2030, the breast cancer drugs market is expected to cross USD 53 billion, driven by: Earlier diagnosis and longer treatment durations Expansion of targeted and immune-based therapies Increased use of combination regimens Growing penetration in emerging markets According to DataM Intelligence analysis: Targeted therapies will remain the largest value segment Hormone receptor-positive cancer will continue to dominate demand Immunotherapy will record the fastest growth Hospitals and cancer centers will remain the primary end users By 2031, breast cancer treatment will be increasingly defined by precision, personalization, and long-term disease management, rather than short-term intervention. Purchase Corporate License | Breast Cancer Drugs Market Intelligence: Executive Takeaway For pharmaceutical leaders and oncology decision-makers, the breast cancer drugs market represents a high-value, innovation-driven opportunity with long-term growth visibility. Organizations that succeed will be those that: Invest in differentiated mechanisms of action Expand biomarker-driven treatment strategies Optimize lifecycle management across therapy lines Balance innovation with market access and affordability As breast cancer continues to shape global oncology priorities, drug innovation will remain central to improving survival outcomes and redefining the standard of care over the next decade. Related Report: Skin Cancer Drugs Market Enters Strategic Expansion Phase as Targeted Therapies and Immuno-Oncology Reshape Treatment Pathways. Gastrointestinal Cancer Drugs Market Enters Strategic Growth Phase as Targeted and Immuno-Oncology Therapies Reshape Treatment Paradigms. Prostate Cancer Drugs Market Enters Strategic Expansion Phase as Targeted and Immuno-Oncology Therapies Reshape Treatment Frameworks. Colorectal Cancer Drugs Market Enters Strategic Growth Phase as Targeted and Immuno-Oncology Therapies Redefine Treatment Strategies Blood Cancer Drugs Market Enters Strategic Expansion Phase as Targeted Therapies and Immuno-Oncology Redefine Oncology Portfolios. About DataM Intelligence DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations. To find out more, visit or follow us on Twitter, LinkedIn, and Facebook. Contact: Sai Kiran DataM Intelligence 4market Research LLP Ground floor, DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Logo: SOURCE DataM Intelligence 4 Market Research LLP 21% more press release views with Request a Demo

Immunotherapy

100 Deals associated with Atezolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10773	Atezolizumab	L01XC32	DB11595

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Extranodal NK-T-Cell Lymphoma	Japan	Chugai Pharmaceutical Co., Ltd.	19 Sep 2025
Advanced Lung Non-Small Cell Carcinoma	European Union	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Iceland	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Liechtenstein	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Norway	Roche Registration GmbH	25 Jul 2024
Breast Cancer	Canada	F. Hoffmann-La Roche Ltd.	13 Mar 2024
Alveolar Soft Part Sarcoma	United States	Genentech, Inc.	09 Dec 2022
PD-L1 positive Non-Small Cell Lung Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	26 May 2022
BRAF V600 mutation-positive Melanoma	United States	Genentech, Inc.	30 Jul 2020
PD-L1 positive Triple Negative Breast Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	19 Jan 2018
Advanced Hepatocellular Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	European Union	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	Iceland	Roche Registration GmbH	20 Sep 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	NDA/BLA	China	Roche Holding AG	25 Feb 2019
Lymphoproliferative Disorders	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Melanoma	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Microsatellite instability-high cancer	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Turcot Syndrome	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Muscle Invasive Bladder Carcinoma	Phase 3	Belgium	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Hong Kong	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Mexico	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Singapore	Hoffmann-La Roche, Inc.	03 May 2021
Locally advanced breast cancer	Phase 3	United States	Roche Diagnostics GmbH	29 Mar 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03755791 (COSMIC-312, CTgov)	Phase 3	Advanced Hepatocellular Carcinoma	837	Cabozantinib+Atezolizumab (Experimental Arm: Cabozantinib + Atezolizumab)	utoqxrqofz(xprawnxfqr) = bxisukbudp ctbjwthfdl (hhuuyhcaym, nviukfbicd - uilxcspart) View more	-	11 Dec 2025
				Sorafenib (Control Arm: Sorafenib)	utoqxrqofz(xprawnxfqr) = gjwotavuau ctbjwthfdl (hhuuyhcaym, znrsihkwcw - eicsclhmvq) View more
ASH2025	Not Applicable	Neoplasms PD-1 \| PD-L1 \| CTLA-4	84,885	Atezolizumab	qtzavthbcs(pketdrrrxx) = xgeprluqct yqeqjhcvwf (qtubcylcrj ) View more	Positive	06 Dec 2025
				toripalimab	qtzavthbcs(pketdrrrxx) = abzxvezuxl yqeqjhcvwf (qtubcylcrj ) View more
ESMO_ASIA2025	Not Applicable	Prostate Neuroendocrine Carcinoma	11	Atezolizumab + carboplatin + etoposide	uqxcaokftf(abjyhwkuie) = fddkkwjupp fgzitqmitd (vqljooibew ) View more	Positive	05 Dec 2025
JPRN-jRCTs041210030 (ESMO_ASIA2025)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	20	Atezolizumab + Carboplatin + nab-paclitaxel	rnjdufwuup(kgouuwzvds) = jqnwtcgjdd exwpicpnfe (qveduvmnnx, 18.8 - 58.2) View more	Positive	05 Dec 2025
ESMO_ASIA2025	Not Applicable	Extensive stage Small Cell Lung Cancer First line	1,096	Atezolizumab + carboplatin + etoposide	zycxpdpmnv(vybozfwxpi) = vndwlrfxqw mmzvkxfalq (mdtmqqiisr ) View more	Negative	05 Dec 2025
				Serplulimab + carboplatin + etoposide	zycxpdpmnv(vybozfwxpi) = eowplkszhv mmzvkxfalq (mdtmqqiisr ) View more
ESMO_ASIA2025	Not Applicable	Unresectable Hepatocellular Carcinoma First line	3,222	Lenvatinib	ppwtmdcigk(fdqadxkmkt): HR = 0.98 (95.0% CI, 0.24 - 4.1)	Positive	05 Dec 2025
				Atezolizumab+Bevacizumab
NCT03836066 (TELMA, CTgov)	Phase 2	Non-squamous non-small cell lung cancer	41	Atezolizumab+Bevacizumab	mmprlcrddp(mrpnaodlnp) = rmhddyxesx tvsgbgzmdd (sxagqhrqqk, mrwcbrlinb - pndcawztue) View more	-	04 Dec 2025
NCT03353831 (AGO-OVAR 2.29, Pubmed \| J Clin Oncol)	Phase 3	Recurrent ovarian cancer PD-L1-positive	574	Atezolizumab + Bevacizumab + Nonplatinum Chemotherapy	tlnzgjdvyr(rfrmqijdnw) = mgjnricvoo umrrjjfrkc (ldrddoqkzj ) View more	Negative	03 Dec 2025
				Placebo + Bevacizumab + Nonplatinum Chemotherapy	tlnzgjdvyr(rfrmqijdnw) = ijscieockw umrrjjfrkc (ldrddoqkzj ) View more
NCT04426825 (ML41256, Pubmed \| Cancer Med)	Phase 2	Non-Small Cell Lung Cancer EGFR mutation‐positive	23	Atezolizumab 1200 mg + Bevacizumab 15 mg/kg (EGFR mutation-positive metastatic non-squamous NSCLC who failed EGFR-TKIs)	nqdgrovdpe(kcebawqkiq) = idqcejjcgd kfbgwwevwf (xqaifvlgef ) View more	Negative	01 Dec 2025
NCT03371017 (IMpassion132, CTgov)	Phase 3	Recurrent Triple-Negative Breast Carcinoma	595	Placebo (Placebo + Chemotherapy)	mksasavfqr(fpjwdppbdk) = ftuhotqxnq fqetcgywku (smmjcqzfsh, rglkekwayl - zokifjyezg) View more	-	12 Nov 2025
				Atezolizumab (Atezolizumab + Chemotherapy)	mksasavfqr(fpjwdppbdk) = kbriwhzfci fqetcgywku (smmjcqzfsh, zqqdqvnrtl - uwbmzsslqu) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.